Remo Panaccione
Appearances
- DateMay 8, 2023Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
Presenters
Speakers
McMaster UniversitySinai Health SystemUniversity of Manitoba - DateMay 8, 2023BACKGROUND The gut microbiome is central to Crohn’s disease (CD) pathogenesis but the relative contribution of different environmental factors to disease compositional variation is unknown…
Presenter
Speakers
McMaster UniversityUniversity of ManitobaSinai Health System - DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Icahn School of Medicine at Mount Sinai - DateMay 9, 2023BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
Presenter
Cedars-Sinai Medical Center - DateMay 9, 2023Background: Patients with inflammatory bowel disease (IBD) often modify their diet in attempt to manage their disease and symptoms. In some cases, dietary changes involve excessive restriction, which may place patients at risk for adverse consequences…
Speakers
Presenter
Icahn School of Medicine, Mount Sinai - DateMay 9, 2023INTRODUCTION: We aimed to investigate the relationship between consumption of ultra-processed foods (UPFs) and: 1) active symptomatic disease and 2) intestinal inflammation in a cohort of adults living with inflammatory bowel disease (IBD)…
Presenter
Speakers
McMaster UniversityUniversity of ManitobaSinai Health System - DateMay 9, 2023INTRODUCTION: We aimed to investigate the relationship between consumption of ultra-processed foods (UPFs) and: 1) active symptomatic disease and 2) intestinal inflammation in a cohort of adults living with inflammatory bowel disease (IBD)…
Presenter
Speakers
McMaster University - DateMay 7, 2023BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…
Speakers
Presenter
- DateMay 9, 2023BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
Presenter
Speakers
Cedars-Sinai Medical CenterUniversity of ManitobaSinai Health System - DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesWestern UniversityCedars-Sinai Medical Center - DateMay 7, 20231) Examine clinical and objective treatment goals 2) Overview of efficacy in patients with moderate to severe Ulcerative Colitis 3) Overview of rapid symptom relief in patients with moderate to severe UC 4) Review long-term safety across six indications including patients with moderate to severe UC…
Presenter
- DateMay 20, 2024Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Presenter
Icahn School of Medicine, Mount Sinai - DateMay 20, 2024BACKGROUND: The Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects (IMAGINE) Strategy for Patient Oriented Research (SPOR) Chronic Disease Network is conducting a five-year multicenter prospective observational cohort study, Mind And Gut Interactions Cohort (…
Presenter
University of ManitobaSpeakers
University of AlbertaQueen's UniversityMcMaster University - DateMay 20, 2024BACKGROUND: Risankizumab (RZB), an anti-interleukin 23p19 monoclonal antibody, demonstrated efficacy for moderately to severely active ulcerative colitis (UC) in the 12-week phase 3 INSPIRE induction study (NCT03398148)…
- DateMay 21, 2024BACKGROUND: Risankizumab (RZB), a monoclonal antibody targeting interleukin-23 p19, was evaluated for maintenance therapy in patients with moderately to severely active ulcerative colitis (UC) and clinical response to RZB intravenous (IV) induction treatment in a phase 3 double-blind, placebo (PBO)…
Presenter
Speakers
Charité - Universitätsmedizin BerlinMayo Foundation for Medical Education and Research - DateMay 21, 2024BACKGROUND: VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis (UC)…
Presenter
Speakers
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven - DateMay 18, 2024Although the cause of Crohn’s disease (CD) is unknown, recent studies have identified a number of biomarkers associated with the risk of developing CD in healthy at-risk individuals…
Presenter
Speakers
Tel Aviv Sourasky Medical CenterSinai Health SystemUniversity of ManitobaWestern UniversityMcMaster University - DateMay 21, 2024Incidence of Crohn's disease(CD) is increasing worldwide. Previous studies suggest that exposure to air pollutants may contribute to the risk of CD…
- DateMay 21, 2024The incidence of inflammatory bowel disease (IBD) is increasing globally. Epidemiological studies suggest an association between consumption of ultra-processed foods (UPFs) and IBD risk…
Presenter